S&P Futures
3,831.50 +6.00 (+0.16%) Dow Futures
30,978.00 +45.00 (+0.15%) Nasdaq Futures
11,695.75 +21.50 (+0.18%) Russell 2000 Futures
1,740.30 +2.00 (+0.12%) Crude Oil
111.04 -0.72 (-0.64%) Gold
1,822.50 +1.30 (+0.07%)
Pharmadrug Inc. (LMLLF)
Chart Events
Performance Outlook
| Previous Close | 0.0218 |
| Open | 0.0263 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0260 - 0.0278 |
| 52 Week Range | 0.0165 - 0.0700 |
| Volume | |
| Avg. Volume | 232,387 |
| Market Cap | 9.187M |
| Beta (5Y Monthly) | 3.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0130 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for LMLLF
Related Research
- PHARMADRUG INCThe Argus Dividend Growth Model PortfolioDividend income, an important element of total return, is often overlooked amid gyrations in the stock market. Between 1930 and 2012, dividend income accounted for 42% of the total return of the S&P 500, according to Hartford Funds. And that's just the average. In some decades, dividends accounted for more than 50% of total returns and even 100% of returns. More recently, dividends have accounted for 15%-20% of returns. Still, in 2018, dividend payments softened the blow when most market indices declined as the Federal Reserve hiked rates. The pattern is being repeated in 2022 as well. Not all dividends are created equal, though, and it is important to understand the difference between the two main categories: high-yield stocks and dividend-growth stocks.RatingFair ValueEconomic Moat17 hours agoArgus Research
- GlobeNewswire
Healthcare Breakthroughs: KZR, NMLSF, AGRX, LMLLF Report Latest Advances in Novel Therapeutics for Inflammatory Diseases, Oncology, and Autism
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Kezar Life Sciences (NASDAQ: KZR), Nova Mentis Life Sciences (OTC: NMLSF), Agile Therapeutics (NASDAQ: AGRX), and PharmaDrug (OTC: LMLLF) (CSE: PHRX). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponential gr
- Newsfile
PharmaDrug Announces Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Esophageal Cancer Study
Results show that oral cepharanthine plus paclitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 28, the final day of dosing compared to paclitaxel alone (p=0.0049)Dose range finding demonstrates that oral cepharanthine-alone was well tolerated in the current in vivo study Toronto, Ontario--(Newsfile Corp. - June 16, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focu
- GlobeNewswire
Healthcare Breakthroughs: NVAX, MITO, LMLLF, NMLSF; Life Sciences Leaders Report Latest Advances in Vaccines, Novel Therapeutics for Autism, Neurodegenerative, Oncology, and Glaucoma
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Novavax (NASDAQ: NVAX), Stealth BioTherapeutics (NASDAQ: MITO) and PharmaDrug (OTC: LMLLF) (CSE: PHRX). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponenti
